Skip to search formSkip to main contentSkip to account menu

AMG531

Known as: AMG 531, Amgen Megakaryopoiesis protein 531 
A recombinant protein with megakarypoiesis stimulating activity. AMG 531 mimics endogenous thrombopoietin (TPO), directly binding to and activating… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

romiplostim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Romiplostim (AMG531, Nplate®) for Secondary Failure of Platelet Recovery After Allogeneic Stem-Cell Transplantation
Abstract 1994 Romiplostim (Rm), a protein that binds to and stimulates the thrombopoietin receptor, has been shown to increase… 
Review
2007
Review
2007
Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection
Background  Patients with chronic liver disease and hepatitis C virus (HCV) frequently experience thrombocytopenia that… 
Review
2007
Review
2007
New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review
Background  Patients with chronic immune thrombocytopenic purpura (ITP) only require treatment if they are bleeding, or prior to… 
2007
2007
Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies
AMG 531 is a novel platelet-stimulating peptibody that stimulates the thrombopoietin (TPO) receptor, and is being studied for its… 
2007
2007
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.
AMG 531 is a novel thrombopoiesis-stimulating peptibody that acts by stimulating the thrombopoietin (TPO) receptor. We report… 
2007
2007
A Comparative Proteomic Analysis of Platelets from Healthy Human Patients and Chronic ITP Patients Receiving AMG 531, a Thrombopoiesis-Stimulating Protein.
AMG 531 is a novel thrombopoiesis-stimulating “peptibody” consisting of an Fc carrier domain linked to 4 identical peptides that… 
2007
2007
AMG 531 for chronic ITP.
n engl j med 356;3 www.nejm.org january 18, 2007 307 is still unknown for carotid stenting. These findings suggest a potential… 
2007
2007
Health-Related Quality of Life (HRQoL) in Patients (Pts) with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531.
Pt-reported outcomes (PROs) are important tools for understanding the effects of treatment for various diseases. We developed the… 
2006
2006
Amgen's TPO mimic faces stiff competition
With seemingly novel science, unsatisfactory existing treatment options and a sizeable potential patient population, it’s hard to… 
2006
2006
Platelet Aggregation Analysis of AMG 531 in a Randomized, Placebo-Controlled Study in Healthy Japanese Subjects.
AMG 531 is a novel thrombopoiesis-stimulating peptibody currently being investigated for the treatment of chronic immune… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)